Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland

Affiliations

¹ Department of Medical Oncology, University Hospital Zurich, Switzerland.
² Centre of Oncology/Haematology and Transfusion Medicine, Cantonal Hospital Aarau, Switzerland.
³ Clinics of Medical Oncology, HFR Fribourg Cantonal Hospital, Switzerland.
⁴ Service and Central Laboratory of Heamatology, University Hospital of Lausanne, Switzerland.
⁵ Department of Haematology, University Hospital Basel, Switzerland.
⁶ Division of Oncology/Haematology, Cantonal Hospital St. Gallen, Switzerland.
⁷ Clinic Bois-Cerf, Onco-haematology, Lausanne, Switzerland.
⁸ Oncology Institute of Southern Switzerland (IOSI), Ospedale San Giovanni, Bellinzona, Switzerland.
⁹ Division of Haematology, University Hospital Geneva, Switzerland.
¹⁰ Medical Oncology and Haematology, Cantonal Hospital Graubuenden, Chur, Switzerland.
¹¹ Department of Medical Oncology, University Hospital of Berne, Switzerland.
¹² Oncology/Haematology, Cantonal Hospital Münsterlingen, Switzerland.
¹³ Department of Medical Oncology, Cantonal Hospital Lucerne, Switzerland.
¹⁴ Oncology Centre Hirslanden & Zurich, Switzerland.

PMID: 25999239
DOI: 10.4414/smw.2015.14100

Free article

Review

Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland

Panagiotis Samaras et al. Swiss Med Wkly. 2015.

Free article

. 2015 Feb 21:145:w14100.

doi: 10.4414/smw.2015.14100. eCollection 2015.

Authors

Affiliations

¹ Department of Medical Oncology, University Hospital Zurich, Switzerland.
² Centre of Oncology/Haematology and Transfusion Medicine, Cantonal Hospital Aarau, Switzerland.
³ Clinics of Medical Oncology, HFR Fribourg Cantonal Hospital, Switzerland.
⁴ Service and Central Laboratory of Heamatology, University Hospital of Lausanne, Switzerland.
⁵ Department of Haematology, University Hospital Basel, Switzerland.
⁶ Division of Oncology/Haematology, Cantonal Hospital St. Gallen, Switzerland.
⁷ Clinic Bois-Cerf, Onco-haematology, Lausanne, Switzerland.
⁸ Oncology Institute of Southern Switzerland (IOSI), Ospedale San Giovanni, Bellinzona, Switzerland.
⁹ Division of Haematology, University Hospital Geneva, Switzerland.
¹⁰ Medical Oncology and Haematology, Cantonal Hospital Graubuenden, Chur, Switzerland.
¹¹ Department of Medical Oncology, University Hospital of Berne, Switzerland.
¹² Oncology/Haematology, Cantonal Hospital Münsterlingen, Switzerland.
¹³ Department of Medical Oncology, Cantonal Hospital Lucerne, Switzerland.
¹⁴ Oncology Centre Hirslanden & Zurich, Switzerland.

PMID: 25999239
DOI: 10.4414/smw.2015.14100

Abstract

The availability of drugs such as thalidomide, bortezomib and lenalidomide changed the landscape in myeloma treatment and has extended the median survival up to 10 years with a substantial improvement in quality of life. This development prompted a Swiss expert panel to re-evaluate the current status and formulate updated clinical recommendations for the diagnosis and treatment of plasma cell myeloma. These recommendations should help clinicians in their decision making to achieve the best outcome based on currently available data.

PubMed Disclaimer

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland

Affiliations

Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland

Authors

Affiliations

Abstract

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical